articleScience Translational MedicineApr 15, 2015GREEN OA

Clonal status of actionable driver events and the timing of mutational processes in cancer evolution

Cancer Research UK · University College London · +4 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

Deciphering whether actionable driver mutations are found in all or a subset of tumor cells will likely be required to improve drug development and precision medicine strategies. We analyzed nine cancer types to determine the subclonal frequencies of driver events, to time mutational processes during cancer evolution, and to identify drivers of subclonal expansions. Although mutations in known driver genes typically occurred early in cancer evolution, we also identified later subclonal "actionable" mutations, including BRAF (V600E), IDH1 (R132H), PIK3CA (E545K), EGFR (L858R), and KRAS (G12D), which may compromise the efficacy of targeted therapy approaches. More than 20% of IDH1 mutations in glioblastomas, and…

No related works found for this paper.

Funding